Stock ATNM ACTINIUM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Actinium Pharmaceuticals, Inc.

Equities

ATNM

US00507W2061

Biotechnology & Medical Research

Market Closed - Nyse
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
8.15 USD +0.49% Intraday chart for Actinium Pharmaceuticals, Inc. -4.12% +60.43%
May. 20 Transcript : Actinium Pharmaceuticals, Inc. - Special Call
May. 15 Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in Tp53 Positive Patients At the Eha 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 Sierra Trial CI

Business Summary

Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.

Number of employees: 49

Sales per Business

USD in Million2022Weight2023Weight Delta
Radiotherapies
100.0 %
1 100.0 % 0 100.0 % -92.14%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
1 100.0 % 0 100.0 % -92.14%

Managers

Managers TitleAgeSince
Sandesh Seth CEO
 Chief Executive Officer 60 12-02-29
Steve O'Loughlin DFI
 Director of Finance/CFO 39 15-10-12
Monideepa Roy CTO
 Chief Tech/Sci/R&D Officer - 21-09-26
Mary Mei Chen CTO
 Chief Tech/Sci/R&D Officer - 20-11-30
Avinash Desai CTO
 Chief Tech/Sci/R&D Officer - 20-11-18
Stephen Dressel PRN
 Corporate Officer/Principal - -
Sunitha Lakshminarayanan PRN
 Corporate Officer/Principal - -
Jenny Hsieh PRN
 Corporate Officer/Principal - -
Paul Diamond LAW
 General Counsel - 21-06-30
Gary Siegel AUD
 Comptroller/Controller/Auditor 66 16-12-31

Members of the board

Members of the board TitleAgeSince
Richard Steinhart BRD
 Director/Board Member 66 13-11-07
C. Nicholson BRD
 Director/Board Member 68 07-12-31
Ajit Shetty BRD
 Director/Board Member 77 17-03-27
Sandesh Seth CEO
 Chief Executive Officer 60 12-02-29
Jeffrey Chell BRD
 Director/Board Member 70 18-03-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 29,783,451 29,147,811 ( 97.87 %) 0 97.87 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
5.581 %
1,640,695 5.581 % 11 M $
Vanguard Fiduciary Trust Co.
4.920 %
1,446,326 4.920 % 9 M $
Michael Bigger
3.636 %
1,068,774 3.636 % 7 M $
District 2 Capital LP
2.811 %
826,428 2.811 % 5 M $
Geode Capital Management LLC
2.027 %
595,720 2.027 % 4 M $
STATE STREET CORPORATION
1.874 %
550,845 1.874 % 4 M $
Northern Trust Investments, Inc.(Investment Management)
0.7190 %
211,349 0.7190 % 1 M $
Verition Fund Management LLC
0.6682 %
196,437 0.6682 % 1 M $
Marshall Wace LLP
0.5187 %
152,469 0.5187 % 1 M $
Brandywine Global Investment Management LLC
0.4953 %
145,600 0.4953 % 955 136 $

Company contact information

Actinium Pharmaceuticals, Inc.

100 Park Avenue 23rd floor

10017, New York

+646 677 3870

http://www.actiniumpharma.com
address Actinium Pharmaceuticals, Inc.(ATNM)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
8.15 USD
Average target price
25.4 USD
Spread / Average Target
+211.66%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ACTINIUM PHARMACEUTICALS, INC. Stock Actinium Pharmaceuticals, Inc.
+60.43% 243M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+11.91% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.60% 106B
BIONTECH SE Stock BioNTech SE
-4.68% 24.28B
ARGENX SE Stock argenx SE
-0.82% 21.96B
GENMAB A/S Stock Genmab A/S
-10.12% 18.16B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.12% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.47% 15.56B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.77% 13.63B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.58% 12.27B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ATNM Stock
  4. Company Actinium Pharmaceuticals, Inc.